clinical trial · NCT04561180
Study to Evaluate the Efficacy and Safety of EG-009A Compared to DEX in Patients With COVID-19 Pneumonia
Evergreen Therapeutics, Inc.·phase2·withdrawn
COVID-19 PneumoniaEG-009AEG-009A PlaceboStandard of CareDexamethasone
brief summary
To study signals of efficacy and safety of a currently available dosage form (IM) of EG-009A in reducing the severity of respiratory disease in patients hospitalized with SARS-CoV-2 virus.
started
Mar 4, 2022
primary completion
May 1, 2023
completion
May 1, 2023
last updated
Jul 28, 2023
official title
A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of EG-009A Compared to Dexamethasone in Patients With Moderate/Severe (Non-intubated, Non-mechanical Ventilation) COVID-19 Pneumonia
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol